However, blocking TGF-β signaling using antibodies restores NK-cell IFN-γ production [139], indicating that targeting TGF-β pathways represents a suitable option to reinvigorate NK cell function and treat HCC patients [290,291,292]. The gene discussed is IFNG; the disease is hepatocellular carcinoma.